The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Andrew W. Roberts, Su Young Kim et al.|Blood|2016Cited by 329
Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemiaJing Deng, Matthew S. Davids, Stacey M. Fernandes et al.|Leukemia|2017Cited by 199
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemiaMatthew S. Davids, Anthony Letai, Jing Deng et al.|Blood|2012Cited by 132
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependenciesElisa ten Hacken, Catherine J. Wu, Rebecca Valentin et al.|JCI Insight|2018Cited by 52
Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLLJing Deng, Matthew S. Davids, Elif Işık et al.|Blood|2015Cited by 16